Skip to main content
Premium Trial:

Request an Annual Quote

Turning Lemons into Lemonade

Successful treatments for Alzheimer's disease have eluded the pharmaceutical industry — every large drug company has had at least one failure, and many small companies have gone out of business trying to find a cure for the tricky mental ailment, In the Pipeline's Derek Lowe says. But there could be a way to get some good out of all those failures. According to the Wall Street Journal, the Coalition Against Major Diseases is developing an open-access database for results from failed Alzheimer's clinical trials. Lowe says Johnson & Johnson, GlaxoSmithKline, Abbott, Sanofi Aventis, and AstraZeneca have already pitched in with data from 11 trials altogether. Lowe says he hopes Eli Lilly, Merck (and Schering-Plough), and Pfizer all pitch in as well. "It'll be difficult to comb through all this to extract something useful, of course. But without sharing the data on these compounds, it would be utterly impossible for anything to come out of their failures," he adds. "I think this is an excellent idea, and well worth extended to other therapeutic areas."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.